Acute ST-elevation myocardial infarction in a 15-year-old boy with celiac disease and multifactorial thrombotic risk

• References

• 1 Osula S, Bell GM, Hornung RS. Acute myocardial infarction in young adults: causes and management. Postgrad Med J 2002; 78: 27-30.
• 2 Kardasz I, De Caterina R. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Int Med 2007; 261: 330-348.
• 3 Lim W, Crowther MA, Eikelboom JW. et al. Management of antiphospholipid antibody syndrome. J Am Med Assoc 2006; 295: 1050-1057.
• 4 Asherson RA, Khamashta MA, Baguley E. et al. Myocardial infarction and antiphospholipid antibodies in SLE and related disorder. Q J Med 1989; 73: 1103-1115.
• 5 Tincani A, Allegri F, Sanmarco M. et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-583.
• 6 Brandt JT, Barna LK, Triplett Da. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost 1995; 74: 1597-1603.
• 7 Segers K, Dahlbäck B, Nicolaes GAF. Coagulation factor V and thrombophilia: Background and mechanisms. Thromb Haemost 2007; 98: 530-542.
• 8 Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
• 9 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
• 10 Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77: 1-43.
• 11 Suehiro Y, Veljkovic DK, Fuller N. et al. Endocytosis and storage of plasma factor V by human megakaryocytes. Thromb Haemost 2005; 94: 585-592.
• 12 Rosendaal FR, Koster T, Vandenbroucke JP. et al. High risk of thrombosis in patients homozigous for factor V Leiden. Blood 1998; 85: 1504-1508.
• 13 Ridker PM, Hennekens CH, Lindpainter K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy young men. N Engl J Med 1995; 332: 912-917.
• 14 Siscovick Ds, Schwartz SM, Rosendaal F. et al. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997; 78: 12.
• 15 Wu O, Robertson L, Langhorne P. et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17-25.
• 16 Nagail N, Lijnen HR, Cleuren ACA. et al. Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice. Thromb Haemost 2007; 98: 858-863.
• 17 Lijfering WM, Coppens M, van de Poel MH. et al. The risk of venous and arterial thrombosis in hyperhomocisteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 457-463.
• 18 Bick RL. Hereditary and acquired thrombophilic disorders. Clin Appl Thromb Haemost 2006; 12: 125-135.
• 19 Keijzer M, Borm GF, Blom HJ. No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis – Results of a meta-analysis of published studies and a large case-only study. Thromb Haemost 2007; 97: 32-37.
• 20 Tsantes AE, Nikolopoulos GK, Bagos PG. et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 907-913.
• 21 Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. Blood 2007; 109: 412-421.
• 22 Saibeni S, Lecchi A, Meucci G. et al. Prevalence of hyperhomocysteinemia in adult glutine-sensitive enteropathy at diagnosis: role of B12, folate, and genetics. Clin Gastroenterol Hepatol 2005; 3: 574-580.
• 23 Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
• 24 Thorburn D, Stanley AJ, Foculis A. et al. Celiac disease presenting with variceal haemorrhage. Gut 2003; 52: 758.
• 25 Miehsler W, Reinish W, Valic E. et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004; 53: 542-548.
• 26 Zenjari T, Boruchowicz A, Desreumaux P. et al. Association of coeliac disease and portal venous thrombosis. Gastroenterol Clin Biol 1995; 19: 953-954.
• 27 Marteau P, Cadranel JF, Messing B. et al. Association of hepatic vein obstruction and coeliac disease in North African subjects. J Hepatol 1994; 20: 650-653.
• 28 Grigg AP. Deep venous thrombosis as the presenting feature in a patient with coeliac disease and homocysteinaemia. Aust NZ J Med 1999; 29: 566-567.
• 29 Morello F, Ronzani G, Cappellari F. Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease. Neurol Sci 2003; 24: 85-89.
• 30 Lee ES, Pulido JS. Nonischemic central retinal vein occlusion associated with celiac disease. Mayo Clin Proc 2005; 80: 157.
• 31 McNeill A, Duthie F, Galloway DJ. Small bowel infarction in a patient with coeliac disease. J Clin Pathol 2006; 59: 216-218.